What is the 13F Pro Quality Score for DARE?

13F Pro ranks Dare Bioscience, Inc. (DARE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DARE's current score at https://13fpro.ai/company/DARE (free sign-up required for the full ranking).

Where does 13F Pro source DARE data?

All Dare Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Dare Bioscience, Inc. files with the SEC under CIK 1401914. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DARE in?

Dare Bioscience, Inc. (DARE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DARE research updated on 13F Pro?

DARE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Dare Bioscience, Inc.(DARE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1401914 DARE stock profile & AI dashboard →

13F Pro Quality Score

10.5/100

Rank #2,909 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DARE Scores 11/100

exact factor attribution · 2026-09-11

DARE's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-0.4 pts

42th pct

Shareholder dilution

-2.3 pts

5th pct

Earnings quality

-3.9 pts

11th pct

Capital efficiency

-4.3 pts

7th pct

Profitability

-7.0 pts

4th pct

Free cash flow

-7.1 pts

3th pct

Scale

-7.3 pts

1th pct

Revenue growth

-9.5 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DARE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Dare Bioscience, Inc. (DARE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DARE at 10.5/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Dare Bioscience, Inc. reports quarterly revenue of $187.5K, net income of $-3.0M, free cash flow of $-6.9M. Top institutional holders of DARE by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, US BANCORP \DE\, based on the most recent SEC filings. DARE trades on the Nasdaq exchange and files with the SEC under CIK 1401914. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dare Bioscience, Inc. directly from SEC EDGAR. Dare Bioscience, Inc.'s 13F Pro composite quality score has ranged between 10 and 39 since 2026, currently 10.5 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about Dare Bioscience, Inc.

Quirks, history, and lore behind DARE — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company headquartered in San Diego and listed on Nasdaq, focused on improving health outcomes for women.
2
The Numbers
A true clinical-stage micro-cap — annual revenue is minimal, and like most drug developers at this stage, it runs on investor capital rather than product sales.
3
The History
The company was founded in the 2010s and built its pipeline specifically around underserved women's health conditions — a segment long neglected by big pharma.
4
The Secret
Its pipeline targets conditions ranging from bacterial vaginosis to female sexual dysfunction — areas where approved treatment options remain frustratingly limited.
5
The Lore
The company has pursued partnerships and licensing deals to advance candidates it couldn't fund alone — a survival strategy common among micro-cap biotech specialists.
6
The Giveaway
The name is a play on daring to tackle women's health — a San Diego biotech whose ticker is literally an invitation to take a chance on the most overlooked patients in medicine.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$187.5K

Net Income

Q2 2026

$-3.0M

Free Cash Flow

Q2 2026

$-6.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10429.4% YoY

$1.0MFY 2025

FY22 $10.0MFY23 $2.8MFY24 $9.8KFY25 $1.0M

Net Income

-230.6% YoY

$-13.4MFY 2025

FY22 $-30.9MFY23 $-30.2MFY24 $-4.1MFY25 $-13.4M

Operating Income

+42.2% YoY

$-13.6MFY 2025

FY22 $-31.4MFY23 $-30.9MFY24 $-23.5MFY25 $-13.6M

EPS (Diluted)

-150.0% YoY

$-1.20FY 2025

FY22 $-0.03FY23 $-0.35FY24 $-0.48FY25 $-1.20

Total Assets

+46.9% YoY

$32.5MFY 2025

FY22 $43.8MFY23 $21.3MFY24 $22.1MFY25 $32.5M

Total Debt

—FY 2025

FY22 —FY23 —FY24 $4.1KFY25 —

Op. Cash Flow

-280.6% YoY

$-9.9MFY 2025

FY22 $-18.1MFY23 $-38.9MFY24 $5.5MFY25 $-9.9M

Free Cash Flow

-309.6% YoY

$-10.3MFY 2025

FY22 $-18.2MFY23 $-39.5MFY24 $4.9MFY25 $-10.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.0M +10429.4%	$9.8K -99.7%	$2.8M -71.9%	$10.0M	$0.00	—
Net Income	$-13.4M -230.6%	$-4.1M +86.6%	$-30.2M +2.5%	$-30.9M +20.0%	$-38.7M -41.2%	$-27.4M
Operating Income	$-13.6M +42.2%	$-23.5M +24.2%	$-30.9M +1.4%	$-31.4M +19.7%	$-39.1M -42.6%	$-27.4M
EPS (Diluted)	$-1.20 -150.0%	$-0.48 -38.8%	$-0.35 -1022.7%	$-0.03 +41.3%	$-0.05 +30.7%	$-0.08
Total Assets	$32.5M +46.9%	$22.1M +3.8%	$21.3M -51.4%	$43.8M -21.5%	$55.8M +639.1%	$7.6M
Total Debt	—	$4.1K	—	—	—	—
Operating Cash Flow	$-9.9M -280.6%	$5.5M +114.1%	$-38.9M -114.8%	$-18.1M +37.1%	$-28.8M -14.0%	$-25.2M
Free Cash Flow	$-10.3M -309.6%	$4.9M +112.4%	$-39.5M -117.5%	$-18.2M +36.9%	$-28.8M -14.0%	$-25.3M

AI Insight: DARE Financial Trends

Dare Bioscience remains pre-revenue with modest quarterly losses, but cash burn accelerated in H1 2026 despite marginal Q4 2025 progress.

• Net loss narrowed from $5M (Q3 2024) to $3M (Q1–Q2 2026); operating loss similarly compressed to $3M run-rate.

• Q4 2025 marked inflection: $1M revenue, positive operating cash flow ($1M), and equity stabilized at $3M.

• H1 2026 operating cash flow deteriorated to $-13M combined; equity eroded from $3M (Q3 2025) to $-1M (Q2 2026).

⚠ Q4 2025 revenue ($1M) did not sustain; Q1–Q2 2026 reverted to $0M. Monitor whether commercialization stalled or was one-time.

⚠ Equity turned negative in Q2 2026 ($-1M) after four quarters of stability. Balance sheet deterioration signals runway pressure.

AI Insight: DARE Ratio Trends

DARE remains deeply unprofitable with ROA deteriorating to -53.3% in Q2 2026, the worst result since Q4 2024.

• ROA swung from -17.8% in Q4 2025 to -53.3% in Q2 2026, reversing a six-month improvement trend.

• Operating margin of -143.7% in Q4 2025 and net margin of -140.8% underscore severe operational losses.

• D/E ratio at 0.00 in Q3 2025 indicates minimal debt, preserving balance-sheet flexibility despite losses.

⚠ ROA volatility persists—swinging from -46.4% to -17.8% to -43.1% to -53.3%—signals unstable earnings.

⚠ No profitability metrics (OpMargin, NPM, ROE, ROIC) available for most quarters; limited visibility on operational trajectory.

Get alerted when DARE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Dare Bioscience, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DARE

VANGUARD CAPITAL MANAGEMENT LLC
$1.4M640,877 sh
GEODE CAPITAL MANAGEMENT, LLC
$295.6K140,093 sh
US BANCORP \DE\
$255.1K120,920 sh
VANGUARD FIDUCIARY TRUST CO
$192.6K91,269 sh
BlackRock, Inc.
$135.6K64,248 sh
STATE STREET CORP
$100.0K47,415 sh
JANE STREET GROUP, LLC
$76.2K36,092 sh
NORTHERN TRUST CORP
$72.2K34,209 sh
HRT FINANCIAL LP
$47.0K22,430 sh
Virtu Financial LLC
$33.0K15,803 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.4M	640,877
GEODE CAPITAL MANAGEMENT, LLC	$295.6K	140,093
US BANCORP \DE\	$255.1K	120,920
VANGUARD FIDUCIARY TRUST CO	$192.6K	91,269
BlackRock, Inc.	$135.6K	64,248
STATE STREET CORP	$100.0K	47,415
JANE STREET GROUP, LLC	$76.2K	36,092
NORTHERN TRUST CORP	$72.2K	34,209
HRT FINANCIAL LP	$47.0K	22,430
Virtu Financial LLC	$33.0K	15,803

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DARE on your watchlist

Track score changes the day Dare Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DARE a good stock to buy?

13F Pro's AI-powered analysis of Dare Bioscience, Inc. (DARE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DARE are available on the DARE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DARE is classified as a small company.

Which hedge funds own DARE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DARE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dare Bioscience, Inc.'s investment landscape.